Advertisement

AIDS and Behavior

, Volume 19, Issue 11, pp 2076–2086 | Cite as

Characteristics Associated with HIV Drug Resistance Among Women Screening for an HIV Prevention Trial in KwaZulu-Natal, South Africa

  • Barbara S. MenschEmail author
  • Pamina M. Gorbach
  • Cliff Kelly
  • Photini Kiepiela
  • Kailazarid Gomez
  • Gita Ramjee
  • Shayhana Ganesh
  • Neetha Morar
  • Lydia Soto-Torres
  • Urvi M. Parikh
Original Paper

Abstract

While the expansion of antiretroviral therapy (ART) in sub-Saharan Africa has reduced morbidity and mortality from HIV/AIDS, it has increased concern about drug resistance. The Microbicide Trials Network 009 study assessed the prevalence of drug-resistance mutations among women at clinical sites in Durban, South Africa who tested seropositive for HIV-1 at screening for the VOICE trial. The objective of this paper was to identify characteristics and behaviors associated with drug resistance. Factors found to be significantly associated with increased resistance were high perceived risk of getting HIV and prior participation in a microbicide trial, a likely proxy for familiarity with the health care system. Two factors were found to be significantly associated with reduced resistance: having a primary sex partner and testing negative for HIV in the past year. Other variables hypothesized to be important in identifying women with resistant virus, including partner or friend on ART who shared with the participant and being given antiretrovirals during pregnancy or labor, or the proxy variable—number of times given birth in a health facility—were not significantly associated. The small number of participants with resistant virus and the probable underreporting of sensitive behaviors likely affected our ability to construct a comprehensive profile of the type of HIV-positive women at greatest risk of developing resistance mutations.

Keywords

HIV drug resistance KwaZulu-Natal HIV-positive women screening for a prevention trial 

Notes

Acknowledgments

We gratefully acknowledge the study participants, the communities and all the sites at which the study took place, health service providers, the South African Medical Research Council Institutional Review Board, and all of the MTN-009 Study Team including the clinical research site leaders Sarita Naidoo, Zakir Gaffoor, Marwah Jenneker, Zola Msiska, Arendevi Pather, Charlene Harichund, Sharika Gappoo, Jessica Philip, Nicola Coumi, Samantha Sukhdeo, Yuki Sookrajh, Leith Kwaan, Vijayanand Guddera and Brodie Daniels. We acknowledge the contributions of Benoit Masse, Paul Edelfsen and Karen Patterson from the Statistical Center for HIV/AIDS Research & Prevention (SCHARP). We also thank Stan Mierzwa and the Population Council IT team that designed and implemented the ACASI software, and Beth Galaska-Burzuk and Judy Jones from the MTN Core for their support during protocol development. The Microbicide Trials Network is funded by the National Institute of Allergy and Infectious Diseases (UM1AI068633, UM1AI068615, UM1AI106707), with co-funding from the Eunice Kennedy Shriver National Institute of Child Health and Human Development and the National Institute of Mental Health, all components of the U.S. National Institutes of Health.

References

  1. 1.
    Abbas UL, Glaubius R, Mubayi A, Hood G, Mellors JW. Antiretroviral therapy and pre-exposure prophylaxis: combined impact on HIV transmission and drug resistance in South Africa. J Infect Dis. 2013;208(2):224–34.PubMedCentralCrossRefPubMedGoogle Scholar
  2. 2.
    Barth RE, van der Loeff MF, Schuurman R, Hoepelman AI, Wensing AM. Virological follow-up of adult patients in antiretroviral treatment programmes in sub-Saharan Africa: a systematic review. Lancet Infect Dis. 2010;10(3):155–66.CrossRefPubMedGoogle Scholar
  3. 3.
    Hamers RL, Sigaloff KC, Wensing AM, et al. Patterns of HIV-1 drug resistance after first-line antiretroviral therapy (ART) failure in 6 sub-Saharan African countries: implications for second-line ART strategies. Clin Infect Dis. 2012;54(11):1660–9.CrossRefPubMedGoogle Scholar
  4. 4.
    Hamers RL, Wallis CL, Kityo C, et al. HIV-1 drug resistance in antiretroviral-naive individuals in sub-Saharan Africa after rollout of antiretroviral therapy: a multicentre observational study. Lancet Infect Dis. 2011;11(10):750–9.CrossRefPubMedGoogle Scholar
  5. 5.
    Parboosing R, Naidoo A, Gordon M, Taylor M, Vella V. Resistance to antiretroviral drugs in newly diagnosed, young treatment-naive HIV-positive pregnant women in the province of KwaZulu-Natal, South Africa. J Med Virol. 2011;83(9):1508–13.CrossRefPubMedGoogle Scholar
  6. 6.
    Manasa J, Katzenstein D, Cassol S, Newell ML, de Oliveira T. Primary drug resistance in South Africa: data from 10 years of surveys. AIDS Res Hum Retroviruses. 2012;28(6):558–65.PubMedCentralCrossRefPubMedGoogle Scholar
  7. 7.
    Hunt GM, Ledwaba J, Basson AE, et al. Surveillance of transmitted HIV-1 drug resistance in Gauteng and KwaZulu-Natal Provinces, South Africa, 2005–2009. Clin Infect Dis. 2012;54(Suppl 4):S334–8.PubMedCentralCrossRefPubMedGoogle Scholar
  8. 8.
    World Health Organization. Executive Summary: Consolidated ARV Guidelines 2013, June 2013. Geneva, Switzerland: World Health Organization; 2013. Available at: http://www.who.int/hiv/pub/guidelines/arv2013/intro/executivesummary/en/index.html. Accessed January, 2014.
  9. 9.
    Hamers RL, Sigaloff KC, Kityo C, Mugyenyi P, de Wit TF. Emerging HIV-1 drug resistance after roll-out of antiretroviral therapy in sub-Saharan Africa. Curr Opin HIV AIDS. 2013;8(1):19–26.CrossRefPubMedGoogle Scholar
  10. 10.
    Choopanya K, Martin M, Suntharasamai P, et al. Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2013;381(9883):2083–90.CrossRefPubMedGoogle Scholar
  11. 11.
    Abdool Karim Q, Abdool Karim SS, Frohlich JA, et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science. 2010;329(5996):1168–74.PubMedCentralCrossRefPubMedGoogle Scholar
  12. 12.
    Van Damme L, Corneli A, Ahmed K, et al. Preexposure prophylaxis for HIV infection among African women. N Engl J Med. 2012;367(5):411–22.PubMedCentralCrossRefPubMedGoogle Scholar
  13. 13.
    Grant RM, Lama JR, Anderson PL, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010;363(27):2587–99.PubMedCentralCrossRefPubMedGoogle Scholar
  14. 14.
    Baeten JM, Donnell D, Ndase P, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med. 2012;367(5):399–410.PubMedCentralCrossRefPubMedGoogle Scholar
  15. 15.
    Thigpen MC, Kebaabetswe PM, Paxton LA, et al. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med. 2012;367(5):423–34.CrossRefPubMedGoogle Scholar
  16. 16.
    Parikh UM, Eskay KA, Hardesty R, et al. HIV-1 resistance outcomes in seroconverters from the MTN 003 (VOICE) Study. Poster presented at: 21st Conference on Retroviruses and Opportunistic Infections (CROI); March 3–6, 2014. Boston, MA.Google Scholar
  17. 17.
    van der Straten A, Stadler J, Luecke E, et al. Perspectives on use of oral and vaginal antiretrovirals for HIV prevention: The VOICE-C qualitative study in Johannesburg, South Africa. J Int AIDS Soc. 2014;17(Suppl 2):19146.PubMedCentralPubMedGoogle Scholar
  18. 18.
    Parikh UM, Kiepiela P, Ganesh S, et al. Prevalence of HIV-1 drug resistance among women screening for HIV prevention trials in KwaZulu-Natal, South Africa (MTN-009). PLoS One. 2013;8(4):e59787.PubMedCentralCrossRefPubMedGoogle Scholar
  19. 19.
    Jourdain G, Ngo-Giang-Huong N, Le Coeur S, et al. Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy. N Engl J Med. 2004;351(3):229–40.CrossRefPubMedGoogle Scholar
  20. 20.
    Gorbach P, Mensch BS, Husnik M, et al. Effect of computer-assisted interviewing on self-reported sexual behavior data in a microbicide clinical trial. AIDS Behav. 2013;17(2):790–800.PubMedCentralCrossRefPubMedGoogle Scholar
  21. 21.
    Liu TF, Shafer RW. Web resources for HIV type 1 genotypic-resistance test interpretation. Clin Infect Dis. 2006;42(11):1608–18.PubMedCentralCrossRefPubMedGoogle Scholar
  22. 22.
    Bennett DE, Camacho RJ, Otelea D, et al. Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009 update. PLoS One. 2009;4(3):e4724.PubMedCentralCrossRefPubMedGoogle Scholar
  23. 23.
    Shisana O, Rehle T, Simbayi LC, et al. South African National HIV Prevalence, Incidence and Behaviour Survey, 2012. Cape Town: HSRC; 2014.Google Scholar
  24. 24.
    van der Straten A, Musara P, Etima J, et al. Disclosure of pharmacokinetic (PK) drug results promotes open discourse on non-adherence among women in VOICE. Oral presentation at: HIV Research for Prevention (R4P) Conference. Session on PrEP and Microbicide Adherence in Women; October 29, 2014; Cape Town, South Africa. OA15.04.Google Scholar
  25. 25.
    Woodsong C, Alleman P, Musara P, et al. Preventive misconception as a motivation for participation and adherence in microbicide trials: evidence from female participants and male partners in Malawi and Zimbabwe. AIDS Behav. 2012;16(3):785–90.PubMedCentralCrossRefPubMedGoogle Scholar
  26. 26.
    Grelotti DJ, Closson EF, Smit JA, et al. Whoonga: potential recreational use of HIV antiretroviral medication in South Africa. AIDS Behav. 2014;18(3):511–8.PubMedCentralCrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2015

Authors and Affiliations

  • Barbara S. Mensch
    • 1
    Email author
  • Pamina M. Gorbach
    • 2
  • Cliff Kelly
    • 3
  • Photini Kiepiela
    • 4
  • Kailazarid Gomez
    • 5
  • Gita Ramjee
    • 4
  • Shayhana Ganesh
    • 4
  • Neetha Morar
    • 4
  • Lydia Soto-Torres
    • 6
  • Urvi M. Parikh
    • 7
  1. 1.Population CouncilNew YorkUSA
  2. 2.Department of Epidemiology, Fielding School of Public HealthUniversity of CaliforniaLos AngelesUSA
  3. 3.Statistical Center for HIV/AIDS Research and PreventionFred Hutchinson Cancer Research CenterSeattleUSA
  4. 4.HIV Prevention Research UnitSouth African Medical Research CouncilDurbanSouth Africa
  5. 5.FHI 360DurhamUSA
  6. 6.Division of AIDS, National Institute of Allergy and Infectious DiseasesNational Institutes of HealthBethesdaUSA
  7. 7.Department of Medicine, Division of Infectious DiseasesUniversity of Pittsburgh School of MedicinePittsburghUSA

Personalised recommendations